0
Critical Care |

Reversal of Hepatorenal Syndrome With the Use of Fix Doses of Vasoconstrictors and Albumin

Anmol Kharbanda*, MD; Vimala Rapaka, MD; Sindhaghatta Venkatram, MD; Gilda Diaz-Fuentes, MD
Author and Funding Information

Bronx Lebanon Hospital Center, Bronx, NY


Chest. 2012;142(4_MeetingAbstracts):311A. doi:10.1378/chest.1388852
Text Size: A A A
Published online

Abstract

SESSION TYPE: Critical Care Case Report Posters

PRESENTED ON: Tuesday, October 23, 2012 at 01:30 PM - 02:30 PM

INTRODUCTION: Hepatorenal syndrome (HRS) is a serious complication of advanced liver cirrhosis; carries a grim prognosis with 2-week mortality rate as high as 80% in untreated type 1 HRS. We present a patient with type 1 HRS where the renal failure resolved with the use of norepinephrine and albumin infusion.

CASE PRESENTATION: 42-year-old-man with advanced hepatitis C and liver cirrhosis (Child’s C, MELD score 38), was admitted to ICU with acute renal failure. Examination revealed an alert and oriented male, in mild distress with massive anasarca; blood pressure 100/60mmHg, respiratory rate 20/min. Laboratory: albumin 1.5g/dl, elevated AST, ALT, bilirubin and serum creatinine (SCr) 2.8mg/dl. He was anuric during the first 12 hours of admission. Urine analysis demonstrated normal sediment, urine sodium 31mEq/L and FENA 0.3%. His SCr was 0.8mg/dl two-months prior. He had not received nephrotoxic medications or diuretics; post-renal obstruction was excluded with a bladder catheter. Abdominal paracentesis and abdomino-pelvic ultrasound were noncontributory. Central venous pressure was 6 cmH2O and intra-abdominal pressure was 4 cmH2O. Intravenous saline and albumin were started. Patient remained anuric with worsening of creatinine (4.6mg/dl) which favored diagnostic of HRS type 1. Infusion of norepinephrine (5ug/kg/ml ) and albumin (1g/kg) were initiated on third day of admission resulting in an increase in urine output and improvement in renal function. Infusions were discontinued on day six (SCr 0.6mg/dL). Two weeks later renal function remains normal.

DISCUSSION: HRS is defined as SCr of >1.5 mg/dl, not reduced with administration of albumin and discontinuation of diuretics. Need to exclude use of nephrotoxic drugs, presence of shock, hypovolemia, peritonitis and parenchymal renal disease. HRS is classified into type 1 (doubling of SCr to >2.5 mg/dl in <2 weeks) and type 2 (gradual increase in SCr to>1.5 mg/dl). HRS is characterized by functional renal vasoconstriction, peripheral vasodilatation and pooling of blood in splanchnic circulation leading to severe reduction in GFR with minimal renal histologic abnormalities. Therapeutic management includes administration of vasoconstrictors. Vasopressin analogues (terlipressin-approved in Europe) are effective in 40-50% of patients. Midodrine and norepinephrine, two α1-adrenergic receptor agonists have been shown to be effective. Liver transplantation is the ultimate treatment for HRS, but vasoconstrictors, TIPS, and/or RRT can be utilized as a bridge to transplantation.

CONCLUSIONS: HRS is a severe complication of liver cirrhosis. Identifying the specific type of renal failure in cirrhosis has prognostic and therapeutic implications. The use of vasoconstrictors should be considered early in the management of HRS.

1) Duvoux C,Zanditenas D, Hezode C,etal. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36:374-380

DISCLOSURE: The following authors have nothing to disclose: Anmol Kharbanda, Vimala Rapaka, Sindhaghatta Venkatram, Gilda Diaz-Fuentes

No Product/Research Disclosure Information

Bronx Lebanon Hospital Center, Bronx, NY

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543